InvestorsHub Logo
Followers 205
Posts 9788
Boards Moderated 6
Alias Born 10/02/2010

Re: laraz5 post# 18638

Thursday, 10/18/2018 12:16:07 AM

Thursday, October 18, 2018 12:16:07 AM

Post# of 21373
LOL, lararz…lets look at facts.

Where is Oncolix since?
New Shell symbol?



Wrong, ONCX is not a shell.

billions more shares?



Wrong, the O/S is relatively unchanged @ roughly 110,000,000.

90% stock loss?



Wrong, the PPS is still trading higher than AEPP lows prior to the R/M.

Toxic Debt?



Notes have been renegotiated with equity and interest accrued until Q2 2019.

Millions of dollars in Interest payments?



Wrong. A relatively small note of $5.4 accrues interest @ a 10% annum with equity and interest accrued until Q2 2019

No Revenue?



That is a given with a pre-revenue bio/pharma company engaged in FDA clinical trials.

No word of any recruits?



Wrong. Results from the original cohort are in ONCX SEC filings and ONCX investor presentations. There are also ONCX CEO interviews available that cover this.

No word on who is producing Prolanta?



BioVectra (a subsidiary of Mallinckrodt PLC NYSE: MNK,) has been producing Prolanta and the former Biovectra CEO is an ONCX board member.

Huge compensation to Execs?



Wrong, the majority of compensation due to ONCX officers (roughly $1,200,000) has been deferred.

Inventor of Prolanta leaving company?



Wrong. The inventor of Prolanta, Dr. Chen was never an ONCX employee.

shareholders wishing ONCX would go back to AEPP?



LOL, not likely.

IMO and FWIW.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.